CorneaGen Revenue and Competitors

Seattle, WA USA

Location

$77M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • CorneaGen's estimated annual revenue is currently $34.1M per year.(i)
  • CorneaGen's estimated revenue per employee is $193,750
  • CorneaGen's total funding is $77M.

Employee Data

  • CorneaGen has 176 Employees.(i)
  • CorneaGen grew their employee count by 21% last year.

CorneaGen's People

NameTitleEmail/Phone
1
VP Quality Assurance and Regulatory AffairsReveal Email/Phone
2
VP Distribution ServicesReveal Email/Phone
3
VP Marketing and CommunicationsReveal Email/Phone
4
Chief Talent Management OfficerReveal Email/Phone
5
Director Information Technology InfrastructureReveal Email/Phone
6
Director Shared ServicesReveal Email/Phone
7
Director Ocular ProgramsReveal Email/Phone
8
Director Distribution Services at CorneaGen BaltimoreReveal Email/Phone
9
Director Business ApplicationsReveal Email/Phone
10
Chief Commercial OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M60%N/AN/A
#2
$0.9M60%N/AN/A
#3
$5.1M336%N/AN/A
#4
$5.7M3742%N/AN/A
#5
$1.4M18-10%N/AN/A
#6
$3.7M48-21%$16MN/A
#7
$1.1M70%N/AN/A
#8
$0.8M5-81%N/AN/A
#9
$2.5M16-27%N/AN/A
#10
$0.8M5-17%N/AN/A
Add Company

What Is CorneaGen?

CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea. Based in Seattle, the company is innovating the next generation of cornea care, from new medical devices and biologics to therapeutics and interventions. CorneaGen supports corneal surgeons and their patients with a spectrum of services, including the latest in innovative products, delivery of the highest quality tissue, surgeon education, and advocacy for patient access and reimbursement policies. www.corneagen.com. New CorneaGen offerings include tissue storage media with antifungal Ampho B, the Geuder Preloaded Glass Cannula for DMEK and Intacs® corneal implants for keratoconus. These products join the recently acquired AcuFocus KAMRA Inlay in CorneaGen's growing line of innovative and affordable therapeutics for corneal surgeons.

keywords:N/A

$77M

Total Funding

176

Number of Employees

$34.1M

Revenue (est)

21%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CorneaGen News

2022-04-13 - Cell therapy biotech raises $120M to advance therapy to treat common cornea condition

CorneaGen, which sells products for eye surgery, spun out Aurion to develop a cell therapy to address the limitations of current treatment...

2022-04-13 - CorneaGen spinout Aura Biotech raises $120M to bring cell ...

Just under a year after spinning out from Seattle-based CorneaGen, Aurion Biotech has raised $120 million to bring its lead cell therapy...

2019-09-06 - Innovative Report on Farsightedness Correction Market with ...

Market Segment by Companies, this report covers: CorneaGen, Revision Optics, Refocus, Presbia. Market Segment by Type, covers: Corneal ...

2019-04-05 - VIDEO: CorneaGen's KeraLink integration nears completion

SCOTTSDALE, Ariz. - At the Cornea360 meeting, Monty Montoya, president and CEO of CorneaGen, discusses the company's integration of ...

2019-02-04 - CorneaGen acquires KeraLink's US operations: An exclusive ...

CorneaGen and KeraLink today announced that CorneaGen will be acquiring all of KeraLink's U.S. eye bank operations and related assets.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$300M1768%N/A
#2
$35M17724%N/A
#3
$34.5M17823%$148M
#4
$69.1M17846%N/A
#5
$23.6M1797%N/A